株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ユーイング肉腫:パイプライン製品の分析

Ewing Sarcoma - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 229774
出版日 ページ情報 英文 255 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.95円で換算しております。
Back to Top
ユーイング肉腫:パイプライン製品の分析 Ewing Sarcoma - Pipeline Review, H1 2017
出版日: 2017年05月31日 ページ情報: 英文 255 Pages
概要

ユーイング肉腫は原発性の骨肉腫で、主に子供や青少年に多く見られます。ユーイング肉腫は子供時代や青少年期に起こりやすく、通常、骨が急速に成長する思春期に進行します。最も一般的な症状は、疼痛と、時折患部が腫れるということがあります。また、一見軽傷に見えた腫瘍患部の骨が折れる子供もいます。

当レポートでは、ユーイング肉腫の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

ユーイング肉腫の概要

治療薬の開発

ユーイング肉腫:治療薬の評価

ユーイング肉腫の治療薬開発に従事している企業

薬剤プロファイル

ユーイング肉腫:休止中のプロジェクト

ユーイング肉腫:開発が中止された製品

ユーイング肉腫:製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9378IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H1 2017, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.

Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 8, 21 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 2 molecules, respectively.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Ewing Sarcoma - Overview
  • Ewing Sarcoma - Therapeutics Development
  • Ewing Sarcoma - Therapeutics Assessment
  • Ewing Sarcoma - Companies Involved in Therapeutics Development
  • Ewing Sarcoma - Drug Profiles
  • Ewing Sarcoma - Dormant Projects
  • Ewing Sarcoma - Discontinued Products
  • Ewing Sarcoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ewing Sarcoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Ewing Sarcoma - Pipeline by Amgen Inc, H1 2017
  • Ewing Sarcoma - Pipeline by Astellas Pharma Inc, H1 2017
  • Ewing Sarcoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Ewing Sarcoma - Pipeline by Cebiotex SL, H1 2017
  • Ewing Sarcoma - Pipeline by Celgene Corp, H1 2017
  • Ewing Sarcoma - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Ewing Sarcoma - Pipeline by CytRx Corp, H1 2017
  • Ewing Sarcoma - Pipeline by EntreChem SL, H1 2017
  • Ewing Sarcoma - Pipeline by Gradalis Inc, H1 2017
  • Ewing Sarcoma - Pipeline by Incyte Corp, H1 2017
  • Ewing Sarcoma - Pipeline by Leadiant Biosciences Inc, H1 2017
  • Ewing Sarcoma - Pipeline by MacroGenics Inc, H1 2017
  • Ewing Sarcoma - Pipeline by Merck & Co Inc, H1 2017
  • Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
  • Ewing Sarcoma - Pipeline by NanoSmart Pharmaceuticals Inc, H1 2017
  • Ewing Sarcoma - Pipeline by NantKwest Inc, H1 2017
  • Ewing Sarcoma - Pipeline by Novartis AG, H1 2017
  • Ewing Sarcoma - Pipeline by Oncomatryx Biopharma SL, H1 2017
  • Ewing Sarcoma - Pipeline by Oncternal Therapeutics Inc, H1 2017
  • Ewing Sarcoma - Pipeline by Pfizer Inc, H1 2017
  • Ewing Sarcoma - Pipeline by Pharma Mar SA, H1 2017
  • Ewing Sarcoma - Pipeline by Recombio SL, H1 2017
  • Ewing Sarcoma - Pipeline by Shionogi & Co Ltd, H1 2017
  • Ewing Sarcoma - Pipeline by Tarveda Therapeutics Inc, H1 2017
  • Ewing Sarcoma - Pipeline by Tesaro Inc, H1 2017
  • Ewing Sarcoma - Dormant Projects, H1 2017
  • Ewing Sarcoma - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Ewing Sarcoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top